Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PEPD | P12955 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488741 | 1.00 | CAPN1 (0.62) | CAPN1CTSBOPRM1GRB2ACE | |
| SCHEMBL20993822 | 0.92 | CAPN1 (0.53) | CAPN1CTSBOPRM1ACEREN | |
| SCHEMBL19492652 | 0.91 | CAPN1 (0.62) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL16488744 | 0.89 | CAPN1 (0.65) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL14682326 | 0.89 | CAPN1 (0.65) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL17229178 | 0.88 | CAPN1 (0.50) | CAPN1CTSBGRB2ACEREN | |
| SCHEMBL14672864 | 0.88 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL20958599 | 0.88 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL14672865 | 0.88 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL14682322 | 0.88 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | CAPN1 1425/4885CTSB 4054/4885OPRM1 10/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CAPN1 866/4885CTSB 4049/4885OPRM1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.